Tom Dilenge

Tom DiLenge joined Flagship Pioneering in 2022 as Senior Partner, Global Public Policy, Regulatory & Governmental Strategy. Tom leads Flagship’s public policy, regulatory, and governmental affairs functions, including development and execution of strategies to advance Flagship’s priorities and positions at the federal, state, and global levels. He also serves as an in-house advisor and expert resource to Flagship’s ecosystem companies.

From 2016 to 2021, Tom was the President of the Advocacy, Law & Public Policy Division of the Biotechnology Innovation Organization (BIO), a 1,000+ member trade association, where he was responsible for strategic and operational management of BIO’s domestic and international advocacy, policy, communications, alliance development, legal and Board governance functions. Prior to this role, Tom served as BIO’s General Counsel and Vice President for Legal and Intellectual Property for a dozen years. Before joining BIO, Tom served as the Chief Counsel and Policy Director for the House Homeland Security Committee, and as Deputy Chief Counsel for Oversight and Investigations on the House Energy and Commerce Committee, where he shepherded passage of several major pieces of legislation and became known as one of the leading policy experts on public health security matters. He began his career in the Washington, D.C. office of the international law firm Mayer Brown working in its general and appellate litigation practice.

Tom graduated summa cum laude, with a degree in Political Science and Economics, from Fordham University, and from the University of Virginia School of Law with honors.

He currently serves as Vice Chair of the Board of Directors for the Adenoid Cystic Carcinoma Research Foundation and is a member of the Life Science Leader Advisory Board. He also currently is an adjunct professor at the University of Virginia’s Frank Batten School of Leadership & Public Policy, where he teaches a course on balancing healthcare innovation and affordability.